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Abstract
Background: To determine the relationships of potential occupational exposure to antineoplastic drugs with
cancer incidence and adverse pregnancy outcomes in a historical prospective cohort study of female registered
nurses (RNs) from British Columbia, Canada (BC).
Methods: Female RNs registered with a professional regulatory body for at least one year between 1974 and 2000
formed the cohort (n = 56,213). The identifier file was linked to Canadian cancer registries. An RN offspring cohort
from 1986 was created by linkages with the BC Birth and Health Status Registries. Exposure was assessed by work
history in oncology or cancer agencies (method 1) and by estimating weighted duration of exposure developed
from a survey of pharmacists and nursing unit administrators of all provincial hospitals and treatment centers and
the work history of the nurses (method 2). Relative risks (RR) were calculated using Poisson regression for cancer
incidence and odds ratios (OR) were calculated for congenital anomaly, stillbirth, low birth weight, and prematurity
incidence, with 95% confidence intervals.
Results: In comparison with other female RNs, method 1 revealed that RNs who ever worked in a cancer center or
in an oncology nursing unit had an increased risk of breast cancer (RR = 1.83; 95% CI = 1.03 - 3.23, 12 cases) and
their offspring were at risk for congenital anomalies of the eye (OR = 3.46, 95% CI = 1.08 - 11.14, 3 cases). Method
2 revealed that RNs classified as having the highest weighted durations of exposure to antineoplastic drugs had an
excess risk of cancer of the rectum (RR = 1.87, 95% CI = 1.07 - 3.29, 14 cases). No statistically significant increased
risks of leukemia, other cancers, stillbirth, low birth weight, prematurity, or other congenital anomalies in the RNs’
offspring were noted.
Conclusions: Female RNs having had potential exposure to antineoplastic drugs were not found to have an
excess risk of leukemia, stillbirth, or congenital anomalies in their offspring, with the exception of congenital
anomalies of the eye, based on only three cases; however, elevated risks of breast and rectal cancer were
observed.
Background
The nursing profession is known to involve occupational
exposures that may have adverse health effects. Lie and
Kjæheim’s [1] review of 19 published epidemiological
studies of nurses, conducted between 1983 and 2001,
c o n c l u d e dt h a tR N sm a yb ea ti n c r e a s e dr i s kf o rb r e a s t
cancer and leukemia related to their work. Some studies
have shown that the offspring of nurses who continue
to work during pregnancy are at increased risk of prena-
tal development of congenital anomalies [2,3].
More specifically, there has been concern regarding
the potential for carcinogenic and teratogenic effects
related to antineoplastic drugs exposure. Antineoplastic
drugs have been used in the treatment of malignant dis-
eases for more than 50 years. There are almost 100 anti-
neoplastic drugs currently in use, many of which are
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nogens [4]. Second malignancies, including leukemia
and bladder cancer, have been reported in patients who
have previously received antineoplastic drugs [4]. Nurses
employed in oncology treatment programs may be occu-
pationally exposed to antineoplastic drugs through inha-
lation of aerosolized drug products and by direct skin
contact of residues on drug vials, contaminated intrave-
nous tubing, drug spillage, and patients’ excreta (urine,
feces, blood, or vomitus), or orally through hand-to-
mouth contact [5]. Although the intensities of exposure
are much less than those of patients receiving treatment,
occupational exposures typically are of longer cumula-
tive duration. Despite the introduction of safety guide-
lines and protective measures, health-care workers can
still be exposed to these toxic drugs, as demonstrated by
detectable levels of biomarkers found in the urine of
nurses and other health professionals, and DNA damage
or chromosomal aberrations observed in their lympho-
cytes and exfoliated buccal cells [6-9]. Mutagenic effects
of antineoplastic drugs provide an explanatory mechan-
ism for elevated risks of cancer and adverse reproductive
outcomes. Antimetabolites, a commonly used class of
antineoplastic drugs, may also affect reproductive out-
comes through folate antagonist activity [10,11].
Several epidemiological studies have been conducted
of the health risks of nurses, in general, as a result of
antineoplastic drug exposure. Increased risks of leuke-
mia and breast cancer were suggested in two studies of
nurses who handled antineoplastic drugs [12,13].
A 1985 study showed an increased risk of congenital
anomalies in the offspring of RNs exposed to antineo-
plastic drugs [14]. Fransman et al. [15], however,
reported that RNs exposed to antineoplastic drugs, rela-
tive to other nurses, had difficulty conceiving, and were
at greater risk of premature delivery and low birth
weight infants, although not at greater risk of sponta-
neous abortion, stillbirth, or congenital anomalies.
W eh a dt h eo p p o r t u n i t yt oe x a m i n eav e r yl a r g e
cohort of registered nurses (RNs) and their offspring in
relation to this occupational exposure. The objectives of
our study were to determine whether a cohort of female
RNs employed since 1974 by oncology/cancer agencies
or by any nursing departments determined to have pos-
s i b l eo rp r o b a b l ee x p o s u r et oa n t i n e o p l a s t i cd r u g s ,i n
the province of BC, had increased risks of cancer (breast
cancer or leukemia, in particular) or adverse pregnancy
outcomes, including stillbirth, congenital anomalies, low
birth weight, and prematurity.
Methods
Study Population
The cohort, described previously [16], consisted of
56,213 females registered with their professional
regulatory body for at least one year between 1974 and
2000 in the province of BC. The cohort file was first
linked with the Canadian Cancer Registry. Observations
were censored for RNs lost to follow-up (i.e., no longer
registered and known to have left Canada before the
end of the study period). Otherwise, they were assumed
to be cancer-free at the end of 1999, unless there was a
cancer diagnosis reported in the cancer registry. The
exposure period was lagged 10 years prior to the inci-
dent cancer cases to allow for a minimum latency per-
iod of 10 years. The cancer cases were categorized by
site according to the World Health Organization’s 9
th
edition of the International Classification of Disease
(ICD-9).
The cohort file was linked to the live and stillbirth
records of the BC Vital Statistics Agency to create an
RN offspring cohort of 22,491 live and 115 stillbirths.
Records of birth weight and gestational age at birth
enabled the identification of offspring with low birth
weight and those born prematurely. Stillbirth was
defined as the delivery of a dead fetus following 20 or
more weeks of gestation. Low birth weight included off-
spring weighing less than 2500 grams and premature
birth included offspring born at a gestational age of less
than 37 weeks. The offspring cohort was linked to the
BC Health Status Registry (HSR) to obtain information
about the presence of congenital anomalies diagnosed
any year (up to 20 years) after birth and, if present, their
type, as categorized according to the ICD-9 classification
system. The HSR was established in 1952 with a man-
date to ascertain, record, and classify “handicapping”
conditions, congenital anomalies, and genetic defects in
the population. Because recording practices were less
consistent in the earlier periods of surveillance, BC Vital
Statistics limited access to HSR data to the interval,
1986 to 2000, to improve upon the consistency in data
quality. Cases were limited to live, singleton offspring to
prevent potential confounding from the adverse effects
associated with stillbirth and multiple-birth pregnancies.
T h es t u d yw a sa p p r o v e db yt h eU n i v e r s i t yo fB r i t i s h
Columbia’s Clinical Research Ethics Board.
Exposure Assessment
For all cohort members, the work history file derived
from the annual registration renewal records contained
the following information for each year the RNs were
registered to practice in the province: name of employer,
type of employer, employment position, level of nursing
education attained, primary area of responsibility, full or
part-time status, and number of hours worked.
Exposure to antineoplastic drugs was assessed by two
methods. The first method (method 1) calculated the
number of years the RN had been employed in the field
of oncology or by the provincial cancer agency, as
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these RNs, the BC Cancer Agency (the organization that
coordinates all provincial cancer centers) was recorded
as the place of employment for the entire study period,
or the nurses reported that they had been employed in
oncology by another hospital. Oncology was added to
the registry as a field of employment in 1996. The BC
Cancer Agency was listed as a place of employment for
the full study period. The majority of nurses in oncology
were employed outside of the BC Cancer Agency (71.0%
for the years 1996-2000), typically in a general hospital
setting. Before 1996, nurses employed in oncology out-
side of the BC Cancer Agency could not be identified.
For the calculation of total years exposed, full-time
employment was assigned a weight of 1.0 and part-time
employment was assigned a weight of 0.5.
A second method of ascertaining exposure to antineo-
plastic drugs (method 2) was based on telephone inter-
views with pharmacists and with senior nurses in
nursing departments from all 94 general hospitals (357
departments) and 19 diagnostic and treatment centers
in BC. Pharmacists were asked about the periods of
time antineoplastic drugs we r eu s e da tt h ef a c i l i t ya n d
about the frequency of use of up to 74 individual anti-
neoplastic drugs. Senior nurses were asked whether any
nurses in their department had administered or mixed
antineoplastic drugs or cared for patients who received
the drugs. Positive responses were followed by further
questions about the probability of exposure (i.e., no
exposure, possible exposure, or probable exposure) by
nursing position (i.e., supervisor/coordinator, clinical
nurse specialist, head nurse/unit manager, charge nurse,
staff nurse) and year. For all positions and years with
possible and probable exposures, these senior nurses
were asked whether specific personal protective equip-
ment was used, and whether waste disposal, spill, and
patient care guidelines were in place and followed.
Finally, if nurses in the department were involved in the
mixing of antineoplastic drugs, the location of the pro-
cedure was queried (i.e., bio-safety cabinet, laminar flow
hood, desk/nursing station, or medication room). Expo-
sure to antineoplastic drugs was then classified as no,
unlikely, possible, or probable using an algorithm cre-
ated by the study hygiene team and completed by the
occupational hygienist (see Figure 1). The algorithm
used the available published evidence about factors
influencing exposures, and was applied to the following
departmental survey data elements for each nursing
position and year: probability that the job involved anti-
neoplastic drug administration; the number of times per
week the drugs were administered; whether the mixing
of antineoplastic drugs was performed; whether gloves
and long-sleeved gowns were used; and whether special
handling procedures were followed for waste disposal,
patient handling, and spill clean-up.
A weighted exposure duration was calculated for each
nurse’s working history during the cohort period. To
acknowledge the skewed distributions of exposures of
nurses to antineoplastic agents [17], and to ensure that
only those with reasonable possibilities of exposure were
attributed exposure-time, a multiplicative weighting
(0.00, 0.0625, 0.25, and 1.00) was assigned to the expo-
sure probabilities from the algorithm (none, unlikely,
possible, and probable exposure, respectively). In addi-
tion, part-time employment was assigned a weight of 0.5
and full-time employment a weight of 1.0. Weighted
exposure durations were cumulated over the person’s
full job history, as follows:
PH j
j
n
j
= ∑ ×
1
where j is the specific job in a specific department for
a specific employer for a specific year, Pj is the weight
for the assigned probabilityo fe x p o s u r ef o rt h a tj o b /
department/employer/year and Hj is the weight for full-
time and part-time employment. A weighted duration of
exposure of 15 days is equivalent to full-time work for
one year (240 days) at a job considered unlikely to be
exposed; a weighted duration of exposure of 60 days is
equivalent to full-time work for one year at a job con-
sidered possibly exposed.
Exposure assessment for the birth outcomes analysis
was determined by the above format for two measures:
(a) estimated exposure during the first trimester of preg-
nancy and (b) cumulative exposure over the ten years
preceding the date of birth.
Statistical Analysis
Poisson regression analysis was performed on the cancer
incidence of the RN cohort, using the R statistical soft-
ware package [18]. Adjustment was made for calendar
year and the age of the RN, and a lag of 10 years was
applied. Based on the distribution of cumulative work
years, the years of work in oncology for method 1 were
categorized into 3 groups: (a) none, (b) < 5 years, and
(c) ≥ 5 years. Weighted duration of exposure to antineo-
plastic drugs for method 2 was also categorized into 3
groups: (a) < 15 days, (b) ≥ 15 to 60 days, and (c) > 60+
days.
Logistic regression analysis was performed on the
reproductive outcomes of the offspring cohort, using
SPSS 16 (SPSS Inc., Chicago, IL). Adjustments were
made for the age of the mother at birth, year of birth,
and the sex of the child. Because of the relatively small
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the years of work in oncology or a cancer center
(method 1) were categorized into 2 groups ("none” or
1+ years ("ever”)), and exposure to antineoplastic drugs
(method 2) was collapsed into two groups (< 15 days
and ≥ 15 days).
For all analyses, two-sided testing with a 5% signifi-
cance level was used, corresponding to a 95% confidence
interval.
Results
Of the 56,213 female RNs who had a work history
between 1974 and 2000, 905 (1.6%) RNs were identified
as ever having been exposed to antineoplastic drugs
according to method 1, based on their employment in
oncology nursing units or at a cancer center, and 7,635
(13.6%) of the 56,213 RNs were assigned at least 15 days
weighted duration of exposure to antineoplastic drugs
according to method 2, based on information acquired
through the agency-based survey.
During 1986-2000, 12,741 RNs gave birth to 22,491
live and singleton offspring, which defined the offspring
cohort (see Table 1). Sixty nine RNs were identified as
having worked in oncology for the time it was available
as a field code (1996-2000), of which 20 (29.0%) were
Figure 1 Algorithm of probability of antineoplastic drug exposure. Algorithm used for individual assessment of probability of exposure,
based on survey questions administered to head nurses of each department included in the study. Based on responses displayed in the boxes
to each of the listed, ordered questions, nurses employed by a given department were allocated in a deterministic manner to either having
unlikely, possible, or probable exposure to antineoplastic drugs.
Table 1 Descriptive characteristics of the RN offspring
cohort, 1986-2000
N%
Total births 23,222
Singletons 22,613 97.4%
Stillbirths
1 147 0.6%
Twins 581 2.5%
Triplets 28 0.1%
Live singletons 22,491
Only child 9,163 40.7%
2 children 8,454 37.6%
≥ 3 children 4,874 21.7%
Males 10,961 48.7%
Females 11,530 51.3%
RN mothers 12,741
Mother’s age at birth
< 30 years 7,943 35.3%
30 - 34 years 9,371 41.7%
≥ 35 years 5,177 23.0%
1Value includes twins and triplets, and cases with missing or incomplete
congenital anomaly diagnosis data.
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ing pregnancy. A total of 141 were identified as having
worked in a cancer center during pregnancy.
As shown in Table 2, having ever worked in oncology
or a cancer center (method 1) was associated with a sig-
nificantly elevated relative risk of breast cancer (RR =
1.83, 95% CI = 1.03 - 3.23, 12 cases). The risks for all
cancers (RR = 1.28, 95% CI = 0.83 - 1.79, 21 cases), or
for cancers specifically of the uterus (RR = 2.58, 95%
CI = 0.96 - 6.94, 4 cases), were elevated, but were not
statistically significant. Cases of other cancers had fre-
quencies below 3 and no cases of leukemia were
observed among those having worked in oncology or a
cancer center.
Table 3 shows the relative risk of cancer by probability
of exposure to antineoplastic drugs (method 2). For
those in the top two exposure categories, the risk of rec-
tal cancer was significantly elevated, based on 14 cases
(RR = 1.87, 95% CI = 1.07 - 3.29), and the risk of breast
cancer was elevated, but was not statistically significant
(RR = 1.12, 95% CI = 0.89 - 1.39, 87 cases). The risks
for all cancers (RR = 1.08, 95% CI = 0.93 - 1.25, 194
cases), and for each other type of cancer, were not sta-
tistically significantly elevated. Three cases of leukemia
were observed among those in the top exposure
categories.
Of 22,491 live births of the offspring cohort, 1,391
(6.2%) were diagnosed with congenital anomalies. One
hundred and seventy (0.8%) mothers (n = 12,741) were
identified as having worked in oncology nursing units or
in a cancer center between 1986 and 2000 during
pregnancy. A total of 2,650 (11.8%) of the mothers in
the cohort were assigned as having had at least 15 days
weighted duration of exposure to antineoplastic drugs in
the 10 years preceding the pregnancy.
Among the offspring of mothers who had ever worked
in oncology nursing units or a cancer center during
their pregnancy (method 1), the risk of all congenital
anomalies or congenital anomalies of the circulatory or
musculoskeletal systems were elevated, but not statisti-
cally significantly; the risko fa n o m a l i e so ft h ee y ew a s
statistically significantly elevated at 3.46 (95% CI = 1.08
- 11.14), but based on only 3 cases (see Table 4). As
shown in Table 5, there were no statistically significant
elevated risks of congenital anomalies among the off-
spring of mothers with exposure to antineoplastic drugs
during the first trimester of pregnancy or over the 10
years preceding pregnancy (method 2). However, the
risk of cleft palate or lip, for the 10-year exposure per-
iod, was notably high, at 1.84 (95% CI = 0.75 - 4.49, 6
cases). Stillbirths were an infrequent outcome for the
offspring cohort, with only 115 cases. There was no
increased risk of stillbirth related to antineoplastic drug
exposure during the first trimester of pregnancy (OR =
0.67, 95% CI = 0.21 - 2.13, 3 cases) or during the 10
years preceding pregnancy (OR = 0.63, 95% CI = 0.31 -
1.30, 8 cases). There were no cases among those who
had worked in oncology nursing units or for a cancer
center during pregnancy.
There were 746 cases of low birth weight and 1,133
cases of prematurity among the offspring cohort.
Among those employed in oncology or a cancer center
Table 2 Relative risk of selected cancer incidence of female registered nurses according to cumulative years worked in
oncology or a cancer center (method 1), 1996-2000 (N = 56,213)
1,2,3,4
Site (ICD-9 code) Employment Duration Observed RR CI (95%) p-value
5
All cancers except non-melanoma skin never 3078 1.00 0.135
< 5 years 14 1.10 0.65-1.87
> 5 years 7 1.89 0.90-3.97
ever 21 1.28 0.83-1.79
Breast (174) never 1274 1.00 0.379
< 5 years 9 1.75 0.91-3.38
> 5 years 3 2.10 0.67-6.53
ever 12 1.83 1.03-3.23
Uterus (179-182) never 302 1.00 0.068
< 5 years 3 2.50 0.80-7.82
> 5 years 1 2.85 0.40-20.38
ever 4 2.58 0.96-6.94
1Based on Poisson regression using a 10-year lag.
2Cancers with an incidence of less than 3 cases were excluded.
3N for ever worked in oncology or cancer center = 905.
4Adjusted for age and calendar year.
5Significance of the trend, derived from chi-square analysis.
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Page 5 of 11Table 3 Relative risk of selected cancer incidence for female registered nurses according to weighted duration of
exposure to antineoplastic agents (method 2), 1974-2000 (N = 56,213)
1,2,3,4
Site (ICD-9 code) Weighted duration of exposure
5 Observed RR CI (95%) p-value
6
All cancers except < 15 days 2905 1.00 0.452
non-melanoma skin 15 to < 60 days 150 1.11 0.94-1.30
≥ 60 days 44 1.00 0.74-1.35
top 2 categories combined 194 1.08 0.93-1.25
Colon (153,159) < 15 days 225 1.00 0.710
15 to < 60 days 11 1.16 0.63-2.13
≥ 60 days < 3
top 2 categories combined 13 0.99 0.56-1.74
Rectum (154) < 15 days 116 1.00 0.037
15 to < 60 days 10 1.85 0.96-3.56
≥ 60 days 4 1.93 0.71-5.25
top 2 categories combined 14 1.87 1.07-3.29
Lung (162) < 15 days 202 1.00 0.867
15 to < 60 days 11 1.24 0.67-2.28
≥ 60 days 3 0.83 0.27-2.61
top 2 categories combined 14 1.22 0.65-1.94
Melanoma (172) < 15 days 191 1.00 0.400
15 to < 60 days 12 1.28 0.71-2.30
≥ 60 days 3 1.28 0.41-4.02
top 2 categories combined 15 1.28 0.75-2.18
Breast (174) < 15 days 1199 1.00 0.267
15 to < 60 days 64 1.08 0.84-1.39
≥ 60 days 23 1.23 0.82-1.87
top 2 categories combined 87 1.12 0.89-1.39
Uterus (179-182) < 15 days 290 1.00 0.696
15 to < 60 days 9 0.72 0.37-1.40
≥ 60 days 7 1.66 0.78-3.53
top 2 categories combined 16 0.95 0.57-1.59
Ovary (183) < 15 days 144 1.00 0.209
15 to < 60 days 6 0.90 0.40-2.06
≥ 60 days < 3
top 2 categories combined 6 0.68 0.30-1.55
Bladder - including in-situ (188) < 15 days 78 1.00 0.394
15 to < 60 days 6 2.00 0.86-4.65
≥ 60 days < 3
top 2 categories combined 7 1.67 0.76-3.67
Brain (191-192) < 15 days 43 1.00 0.292
15 to < 60 days 3 1.76 0.54-5.80
≥ 60 days < 3 1.88 0.26-13.87
top 2 categories combined 4 1.79 0.63-5.10
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1.41, 95% CI = 0.44 - 4.54, 3 cases) and prematurity
(OR = 1.88, 95% CI = 0.80 - 4.41, 6 cases) were both
elevated, but were not statistically significant. There
were no increased risks of low birth weight or prematur-
ity, respectively, related to antineoplastic drugs exposure
during the first trimester of pregnancy (OR = 0.97, 95%
CI = 0.43 - 2.20, 6 cases; OR = 1.05, 95% CI = 0.56 -
2.00, 10 cases) or during the 10 years preceding preg-
nancy (OR = 0.67, 95% CI = 0.32 - 1.42, 7 cases;
OR = 0.62, 95% CI = 0.33 - 1.17, 10 cases).
Discussion
This cohort of RNs who worked in BC between 1974
and 2000 showed a slightly increased but non-significant
risk of all cancers if they had potential exposure to anti-
neoplastic drugs. The risk of breast cancer was signifi-
cantly elevated among those who had ever worked in
oncology nursing units or for a cancer center, which
showed a possible trend of increasing incidence with
increasing years of work. However, this increase was ele-
vated but not statistically significant in RNs classified as
Table 3 Relative risk of selected cancer incidence for female registered nurses according to weighted duration of
exposure to antineoplastic agents (method 2), 1974-2000 (N = 56,213)
1,2,3,4 (Continued)
Thyroid (193) < 15 days 82 1.00 0.408
15 to < 60 days 4 0.93 0.34-2.56
≥ 60 days
<3
top 2 categories combined 4 0.74 0.27-2.05
Ill-defined (195) < 15 days 81 1.00 0.181
15 to < 60 days 5 1.33 0.54-3.31
≥ 60 days 3 2.09 0.66-6.65
top 2 categories combined 8 1.54 0.74-3.21
Lymphatic & Hematopoietic < 15 days 219 1.00 0.482
(200-208) 15 to < 60 days 9 0.93 0.47-1.82
≥ 60 days < 3
top 2 categories combined 11 0.84 0.46-1.55
Non-Hodgkin Lymphoma < 15 days 121 1.00 0.643
(200, 202) 15 to < 60 days 6 1.06 0.47-2.43
≥ 60 days < 3 0.49 0.07-3.52
top 2 categories combined 7 0.91 0.42-1.96
Leukemia (204-208) < 15 days 59 1.00 0.930
15 to < 60 days < 3
≥ 60 days < 3
top 2 categories combined 3 0.89 0.27 - 2.88
1 Based on Poisson regression using a 10-year lag.
2 Cancer with an incidence of less than 3 were excluded.
3 N for top 2 categories of antineoplastic drug exposure = 7,635.
4 Adjusted for age and calendar year.
5 A weighted duration of exposure of 15 days is equivalent to full-time work for one year (240 days) at a job considered unlikely to be exposed; a weighted
duration of exposure of 60 days is equivalent to full-time work for one year at a job considered possibly exposed.
6 Significance of the trend, derived from chi-square analysis.
Table 4 Risk of congenital anomalies among the
offspring of RNs employed in oncology nursing units or
a cancer center during pregnancy (method 1), 1996-2000
(N = 22,491)
1,2
Congenital anomaly category
(ICD9 code)
Employed Cases OR
3 CI (95%)
All congenital anomalies (740-
759)
never 1024 1.00
ever 17 1.42 0.86-2.36
Eye (743) never 69 1.00
ever 3 3.46 1.08-
11.14
Circulatory system (747) none 94 1.00
ever 3 2.68 0.84-8.59
Musculoskeletal system never 335 1.00
(754-756) ever 5 1.
21
0.49-2.96
1Congenital anomaly types with an incidence of less than 3 cases were
excluded.
2N for ever employed in oncology or cancer center = 190.
3Adjusted for sex, year of birth, and age of mother.
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Page 7 of 11Table 5 Risk of congenital anomalies among the offspring of RNs according to weighted duration of exposure to
antineoplastic drugs (method 2), 1986-2000 (N = 22,491)
1,2
Congenital anomaly category
(ICD9 code)
Weighted duration of
exposure
3
Exposure during first trimester of
pregnancy
Exposure during 10 years preceding
pregnancy
cases OR
4 CI (95%) cases OR
4 CI (95%)
All congenital anomalies < 15 days 1,328 1.00 1229 1.00
(740-759) ≥ 15 days 63 0.93 0.72-1.21 162 0.98 0.82-1.16
Nervous system < 15 days 51 1.00 47 1.00
(740-742) ≥ 15 days < 3 6 0.96 0.41-2.24
Eye < 15 days 89 1.00 81 1.00
(743) ≥ 15 days 6 1.31 0.57-3.00 14 1.26 0.71-2.22
Ear, face, neck < 15 days 85 1.00 82 1.00
(744) ≥ 15 days 4 0.96 0.35-2.64 7 0.64 0.30-1.39
Heart < 15 days 137 1.00 127 1.00
(745-746) ≥ 15 days 10 1.44 0.75-2.74 20 1.15 0.72-1.84
Other circulatory system < 15 days 127 1.00 115 1.00
(747) ≥ 15 days 8 1.26 0.61-2.58 20 1.28 0.79-2.06
Cleft palate/lip < 15 days 29 1.00 25 1.00
(749) ≥ 15 days < 3 6 1.84 0.75-4.49
Upper alimentary tract < 15 days 83 1.00 81 1.00
(750) ≥ 15 days 4 0.93 0.34-2.55 6 0.55 0.24-1.25
Other digestive system < 15 days 35 1.00 32
(751) ≥ 15 days < 3 5 1.17 0.46-3.01
Genital organs < 15 days 213 1.00 192 1.00
(752) ≥ 15 days 6 0.55 0.24-1.25 27 1.06 0.70-1.59
Urinary system < 15 days 101 1.00 93 1.00
(753) ≥ 15 days 5 0.97 0.39-2.38 13 1.05 0.59-1.88
Musculoskeletal system < 15 days 443 1.00 419 1.00
(754-756) ≥ 15 days 18 0.80 0.49-1.28 42 0.74 0.54-1.02
Integument < 15 days 96 1.00 88 1.00
(228, 757) ≥ 15 days 5 1.01 0.41-2.49 13 1.08 0.60-1.94
Chromosomal anomalies < 15 days 60 1.00 56 1.00
(758) ≥ 15 days < 3 4 0.54 0.20-1.49
Multiple anomalies < 15 days 15 1.00 13 1.00
(759.7-759.8) ≥ 15 days < 3 3 1.76 0.50-6.19
1 Congenital anomalies with an incidence of less than 3 cases were excluded.
2 Nf o r≥ 15 days of antineoplastic drug exposure during first trimester of pregnancy = 1,062; during 10 years preceding pregnancy = 2,650.
3 A weighted duration of exposure of 15 days is equivalent to full-time work for one year (240 days) at a job considered unlikely to be exposed; a weighted
duration of exposure of 60 days is equivalent to full-time work for one year at a job considered possibly exposed.
4 Adjusted for sex, year of birth, and age of mother.
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Page 8 of 11potentially exposed to antineoplastic drugs, based on a
survey-based exposure assessment protocol. An
increased risk of cancer of the rectum was observed in
RNs determined to have had a probability of exposure
to antineoplastic drugs. No increased risk of any other
cancer type, including leukemia, was observed using
either exposure assessment method.
It has been well established that nurses in oncology
who handle antineoplastic drugs have increased frequen-
cies of biomarkers of exposure, including chromosomal
aberrations and sister chromatid exchanges [19-22].
However, to date, very few relevant epidemiological stu-
dies have estimated RNs’ cancer risk related to exposure
to antineoplastic drugs. A linkage study of Danish
nurses who worked in oncology departments, preparing
and administering antineoplastic drugs, reported a sta-
tistically significantly increased relative risk (RR = 10.65)
for one site, leukemia, based on 2 cases [12]. A nested
case-control study of 59 breast cancer cases from an
I c e l a n d i cc o h o r ts t u d yo ff e m a l en u r s e sf o u n dt h a tt h e
risk estimates were highest (although not statistically
significant and based on 7 cases) among those who had
ever handled cytotoxic drugs (OR = 1.65, 95% CI = 0.53
- 5.17), after adjustment for year of birth, breast cancer
in a first-degree relative, marital status, and nulliparity
[13]. Our finding of a significantly increased risk of
breast cancer among RNs who had ever worked in
oncology or a cancer center provides some additional
evidence of this association and supports the relevance
of further investigating occupational risk factors for
nurses. In future research about nursing and cancer
incidence, consideration should also be given to the pos-
sible influence of mammography screening rates. It is
p o s s i b l et h a to n c o l o g yn u r ses, who directly care for
women with breast cancer, are predisposed to mammo-
graphy screening participation and thus are subject to
an over-detection bias. It is recognized that some breast
cancers, if undetected and thus not treated, would not
progress and that some women are “over-diagnosed”
[23,24].
The mutagenic effects of antineoplastic drugs may
increase the risk of congenital anomalies and stillbirth
among exposed nurses. Of three case-control studies,
one showed an odds ratio of 4.7 (95% CI = 1.2 - 18.1)
for congenital anomalies among those exposed to anti-
neoplastic drugs at least once a week [14], one showed a
relative risk of 1.7 (95% CI = 1.0 - 2.8) for spontaneous
abortions among occupationally exposed nurses [25],
and a third showed an odds ratio of 2.3 (95% CI = 1.2 -
4.4) for fetal loss among nurses exposed during their
first trimester of pregnancy [26]. A cross-sectional study
observed 8 congenital anomalies among offspring of 152
physicians and nurses who administered antineoplastic
drugs during pregnancy (4.05 expected; p = 0.05) [27].
More recent studies have shown few reproductive risks
from antineoplastic drug exposure. A questionnaire-
based study found log-linear odds ratios of 1.20 (95% CI
= 0.98 - 1.47) for stillbirth and 0.97 (95% CI = 0.86 -
1.09) for congenital anomalies among the offspring of
nurses exposed to antineoplastic drugs [12]. Two case-
control studies found odds ratios of 1.02 (95% CI = 0.47
- 2.06) and 2.2 (95% CI = 0.7 - 7.2) for congenital
anomalies among the offspring of nurses who handled
antineoplastic drugs, compared with nurses without
exposure [12,28]. A recent meta-analysis of four studies
of nurses’ exposure to antineoplastic drugs estimated an
odds ratio for congenital anomaly incidence of 1.64
(95% CI = 0.91 - 2.94) [7].
In our study, the risk of congenital anomalies of the
eye was significantly increased in the offspring of RNs
who had ever worked in oncology nursing units or for
cancer centers during pregnancy (method 1), although
this estimate was based on only 3 cases. The risks for
other congenital anomalies among this employment
group were also notably elevated, but not statistically
significantly and were limited by the low frequency of
cases. The comparatively higher risk of all congenital
anomalies in the employment group may suggest an
oncology/cancer agency-specific effect that is perhaps
diluted in the broader department-based exposure
assessments. The risks of stillbirth, low birth weight,
and prematurity were not significantly increased among
RNs potentially exposed to antineoplastic drugs,
assessed through either their employment in oncology
or estimated weighted duration of exposure.
According to the BC Cancer Agency Benefit Drug
List, there was an increase in the number of different
antineoplastic drugs used, from 66 in 1986 to 88 in
2000. Standardized safety practices for handling antineo-
plastic drugs and other hazardous materials were estab-
lished in 1985. However, a recent review of methods
used to monitor occupational exposure to antineoplastic
drugs concluded that, despite the introduction of safety
guidelines and protective measures, health-care workers
can still be exposed [8]. Nonetheless, the adoption of
these practices may partly account for the predomi-
nantly null or non-significant risks observed in this and
other recent studies [15,12,28].
Whereas many previous studies were questionnaire-
based and were, therefore, susceptible to exposure recall
and selection biases, our record linkage used compre-
hensive recruitment of an employment group based on
registry-derived data and allowed for complete ascer-
tainment of outcomes according to standardized medi-
cal reporting systems. Furthermore, the historical
prospective design of the study meant that exposure
variables were assessed independently from health
outcomes.
Ratner et al. BMC Nursing 2010, 9:15
http://www.biomedcentral.com/1472-6955/9/15
Page 9 of 11Despite our large sample size, limitations of our study
arise from limited statistical power associated with the
small numbers of cases and the low prevalence of expo-
sure, possibly leading to missed associations, as well as
the testing of multiple hypotheses, such that a statisti-
cally significant association may have occurred by
chance alone.
As is common in historical cohort studies, we had no
information about potential confounding factors related
to lifestyle; however, all comparisons were within the
nursing profession, a narrow, well educated, socioeco-
nomic stratum. Nurses have been documented to have
healthier habits than the population as a whole, but
there have been temporal patterns, for example strong
declines in smoking rates among US nurses in the last
30 years (33% smokers in 1976 vs. 8.4% in 2002/2003
[29]). There also were temporal patterns in antineoplas-
tic drug use in the British Columbia healthcare agencies
during the study period (e.g., hand mixing of the drugs
was completed in 45% of the facilities in the 1970 s and
1980 s, but only 8% in the 1990 s and later). If smoking
and antineoplastic drug exposures were correlated and
both related to the outcomes of interest, there could be
uncontrolled confounding in the study results. In a
recent study of 1,147 live births among nurses, control-
ling for parity, smoking, alcohol, coffee, multivitamin,
and folic acid intake did not materially change the effect
estimates for congenital anomalies [15].
We were not able to adjust for other chemical expo-
sures in the RNs’ workplaces or other environments.
Unfortunately, there is little if any data available about
the presence and usage of such chemicals. We are left
to assume that the RNs exposed to antineoplastic drugs
were similar to the unexposed RNs with respect to their
opportunity to having been exposed to other toxins.
The exposure assessment methods used in the study
were crude and may have resulted in misclassification of
exposure. For example, in method 1, most nurses work-
ing in oncology departments were outside of the cancer
centers and were not identifiable in the registry, prior to
1996. This likely led to underestimation of the number
of exposed RNs but would have been highly specific.
The survey (method 2) identified relevant departments
in general hospitals and treatment centers that adminis-
tered antineoplastic drugs and ascribed individual nurses
therein with a probability ofe x p o s u r e .W i t h i nt h e s e
departments, some of the nurses ascribed a probability
of exposure may not have been exposed and, within
other departments, some of the nurses may have been
missed because of poor information recall. This likely
resulted in misclassification, which would have biased
the effect estimate toward the null. Nonetheless, the
method was novel in its attempt to more precisely
characterize exposure estimates of a cohort of nurses
through the use of relevant questions about employment
history that were simple enough to assume sufficient
recall for an approximation of exposure; that is, the clas-
sification was broadly based.
The premise underlying method 1 was that the oncol-
ogy departments, as cancer treatment facilities by defini-
tion, would have consistently used antineoplastic drugs,
whereas other departments (in general hospitals and
other agencies) may not have used them, or when they
did, perhaps they did so with less regularity. This
method more definitively assigned exposure through the
use of reliable employment records, limited the exposure
group, and introduced some uncertainty about the
unexposed group (it may have contained nurses from
nursing departments with possible exposure).
Consequently, these limitations of the assessments of
exposure may have affected their accuracy and could
possibly have resulted in an underestimation of the risks
associated with exposure to antineoplastic drugs or have
distorted the shape of the dose-response relationship.
For instance, the relative risk found for breast cancer
using method 2, as opposed to method 1, was elevated,
but not statistically significant.
Conclusions
In summary, RNs potentially exposed to antineoplastic
drugs through their employment had an elevated risk of
breast and rectal cancer. There was no demonstrated
risk of other types of cancer or of adverse reproductive
outcomes, apart from an elevated risk for anomalies of
the eye based on three cases. Further investigations,
including more detailed measurements of exposures and
dosages received, may be helpful in evaluating the
mechanisms by which occupational exposures to anti-
neoplastic drugs may act as risk factors for cancer and
adverse reproductive outcomes.
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